Navigation Links
Talecris Biotherapeutics Launches PROLASTIN®-C in Canada
Date:11/2/2010

RESEARCH TRIANGLE PARK, N.C., Nov. 2, 2010 /PRNewswire/ -- Talecris Biotherapeutics (Nasdaq: TLCR) announced today the Canadian launch of PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human])(A1PI), a more concentrated and purified formulation of PROLASTIN®, the only approved alpha1-augmentation therapy in Canada for more than 20 years.  PROLASTIN-C delivers twice the active protein per milliliter as PROLASTIN, cutting the infusion volume and time in half when given at the recommended rate of 0.08 mL/kg/min. 

PROLASTIN-C has replaced PROLASTIN in Canada. Both products are indicated for chronic augmentation and maintenance therapy in adults who have emphysema due to a genetic condition known as alpha1-antitrypsin (AAT) deficiency. The active protein in PROLASTIN-C increases or "augments" protein levels in AAT-deficient patients.

"Talecris research and development scientists continually strive to enhance the overall quality of our products by incorporating the latest advances in technology," said Joel Abelson, Senior Vice President & General Manager, Portfolio Management & International Business. "PROLASTIN-C is an example of our commitment to supporting patients who use protein therapies to treat their rare and life-threatening conditions."

PROLASTIN-C contains the same active ingredient as PROLASTIN. Clinical studies demonstrated that the products are equally effective at raising alpha1 levels, and that PROLASTIN-C has an adverse event profile consistent with that of PROLASTIN.  (http://www.biomedcentral.com/1472-6904/10/13

The most common drug-related adverse reactions during clinical trials in >/=1% of subjects were chills, malaise, headache, rash, hot flush, and pruritus. The most serious adverse reaction observed during clinical studies with PRO
'/>"/>

SOURCE Talecris Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Talecris Biotherapeutics Receives FDA Approval for Gamunex®-C
2. Talecris Biotherapeutics to Report Third Quarter 2010 Financial Results
3. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
4. Talecris Forms Partnership to Co-Promote Life-Saving Rabies Products
5. Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C
6. Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
7. Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
8. Garnet BioTherapeutics Announces First Patient Treated in Trial of New Therapy for Improvement in Scar Appearance
9. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
10. Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing
11. Oxygen Biotherapeutics, Inc. Expands Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... SAN DIEGO , July 29, 2015  ViaCyte, Inc., a ... therapy for the treatment of diabetes in clinical trials, today announced ... called STEP ONE, or S afety, T olerability, and ... One Diabetes.  The new site, which is the first ... of Alberta Hospitals in Edmonton , Alberta.  ...
(Date:7/29/2015)... -- Fifty groups representing 500,000 patients, doctors, and researchers will ... AllTrials campaign in the US. The global campaign calls ... be registered and the results from it reported. ... explains: "Patients want the treatments that are best for ... Unfortunately, we now know that around half of all ...
(Date:7/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hmjqff/global_wound_care ... "Global Wound Care Markets (Twelve Country Analysis: Germany, ... China, India, Brazil, Australia, South Korea)" report ... provides a competitive market summary. The wound care ... offerings and product maturity. Several of the products ...
Breaking Medicine Technology:ViaCyte Announces Second Clinical Trial Site at University of Alberta 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 3ViaCyte Announces Second Clinical Trial Site at University of Alberta 4Fixing Your Medicine: AllTrials Campaign Launches in US 2Fixing Your Medicine: AllTrials Campaign Launches in US 3Global Wound Care Markets 2015 2
(Date:7/29/2015)... Minneapolis, Minnesota (PRWEB) , ... July 29, 2015 , ... ... The Sofia Fund, which invests in women-led, growth companies and is led by a ... Investors have responded positively, and voted with their dollars to be a part ...
(Date:7/29/2015)... , ... July 29, 2015 , ... CanAm Enterprises, LLC ... USCIS over the past month! I-829 approvals have been granted to investors in four ... Angeles, the Kimpton Lafayette Hotel project in Philadelphia, and the Valley Forge Convention Center ...
(Date:7/29/2015)... ... July 29, 2015 , ... Inspired by ... in March, Steven W. Meier M.D., a prominent orthopedic surgeon and regenerative medicine ... with demonstrated financial need. , “We are thrilled for this opportunity to offer ...
(Date:7/29/2015)... ... ... Employee Fiduciary, LLC announces the launch of its new, online Financial Advisor ... administered, years in business, and credentials of all Employee Fiduciary financial advisor partners ... Fiduciary. A search can be done by zip code so a plan sponsor can ...
(Date:7/29/2015)... ... 29, 2015 , ... TransFlip is an all new dynamic transition pack for ... FCPX, these transitions are easy to apply and modify for any skill-level user. TransFlip ... 60 preset styles, kinetic flipping panel animations are just a few clicks away. , ...
Breaking Medicine News(10 mins):Health News:Sofia Fund Surpasses Investor Goals 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3Health News:Orthopedic Surgeon Announces New Pro Bono Prolotherapy and Regenerative Medicine Clinic for Underserved Communities in Los Angeles 2Health News:Employee Fiduciary Launches Financial Advisor Directory 2Health News:Pixel Film Studios Releases FCPX Transition TransFlip for FCPX 2
... ... effective in aiding weight loss. Users say it helps them lose up to 40 ... ... of "super chocolate" has been fast increasing popularity among international models and athletes as ...
... (embargo: 6 May, 16:45 CEST) , J. Hicks, USA, ... from very small samples , Researchers have developed a powerful ... The breakthrough allows them to study in fine detail the ... receptor status of HER2+ breast cancer correlates with response to ...
... of Pediatrics, Global Health and Epidemiology & Biostatistics ... has been selected by the J. William Fulbright ... Fulbright Scholarship. Beginning in August 2010, Dr. Mandalakas ... in collaboration with Stellenbosch University to study the ...
... ... ... CosmoCom the global leader in Contact Center Consolidation 2.0, announced that its healthcare contact ... (LISA). Presented by the Long Island Software and Technology Network (LISTnet), the LISA recognizes ...
... ... ... for the Skinny on Willpower! The publishing industry is in the midst of a revolutionary change, ... The Skinny On series. The series, recent hit, The Skinny On Willpower , addresses ...
... Urns.com Offers New Biodegradable Urns ... More Give People The Option To Have More A Eco-Friendly Funeral. , ... Goleta, CA (PRWEB) May 6, 2010 –- When a loved one ... where those left behind need to consider not only the wishes of the deceased, but also ...
Cached Medicine News:Health News:Super Fat-Melting Chocolate Recipe Revealed 2Health News:Super Fat-Melting Chocolate Recipe Revealed 3Health News:IMPAKT Breast Cancer Conference press program 2Health News:CWRU global TB expert receives prestigious Fulbright Scholar Award 2Health News:CWRU global TB expert receives prestigious Fulbright Scholar Award 3Health News:CosmoCom Wins Software Award for CosmoHealth 2Health News:CosmoCom Wins Software Award for CosmoHealth 3Health News:Readers and Reviewers Rave about 'The Skinny On Willpower' 2Health News:Readers and Reviewers Rave about 'The Skinny On Willpower' 3Health News:Readers and Reviewers Rave about 'The Skinny On Willpower' 4Health News:Urns.com Announces Urns As An Eco Friendly Burial Alternative 2
For vacuum-driven processing of spin columns; Reduced sample handling and accelerated processing; Parallel sample processing using QIAGEN spin columns; Easy cleaning of internal components by simpl...
Inquire...
... The Perfect Single Vac ... one 96-well plate in 30 ... with an "open/closed" switch and ... for easy operation. contains vacuum ...
... has been designed for use with Bioneer's ... can handle 96 samples (Plasmid DNA, Genomic ... and purification. While conventional kits use centrifugal ... BioVac 96 Vacuum Manifold uses vacuum pressure ...
Medicine Products: